{"filing":{"accession_number":"0001829126-26-006695","cik":"0002079109","ticker":null,"company_name":"Veraxa Biotech Holding AG","form":"6-K","filing_date":"2026-06-18","report_date":null,"primary_document":"veraxabiotech_6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2079109/000182912626006695/veraxabiotech_6k.htm"},"events":[{"id":12101,"run_id":10663,"accession_number":"0001829126-26-006695","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"This press release announces the establishment of in vitro proof-of-concept data for VERAXA's novel BiTAC-ADC technology platform and the company's intention to launch partnering discussions at BIO International Convention 2026. The disclosure is primarily operational and strategic in nature—it describes a technology validation milestone and business development activity (partnering discussions) rather than a financial event, executive change, M\u0026A transaction, or other specifically enumerated event type. The data validation and partnering initiative represent material operational progress for an emerging biotech company, affecting investor assessment of the company's pipeline and commercial prospects.","company_name":"Veraxa Biotech Holding AG","ticker":null,"filing_date":"2026-06-18","form":"6-K","submitted_at":null,"items":[{"id":8859,"accession_number":"0001829126-26-006695","item_number":"EX-99.1","item_title":"veraxabiotech_ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces the establishment of in vitro proof-of-concept data for VERAXA's novel BiTAC-ADC technology platform and the company's intention to launch partnering discussions at BIO International Convention 2026. The disclosure is primarily operational and strategic in nature—it describes a technology validation milestone and business development activity (partnering discussions) rather than a financial event, executive change, M\u0026A transaction, or other specifically enumerated event type. The data validation and partnering initiative represent material operational progress for an emerging biotech company, affecting investor assessment of the company's pipeline and commercial prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-08fd3440","taxonomy_version":"v1.2","classified_at":"2026-06-21T19:02:52.583393+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":8859,"accession_number":"0001829126-26-006695","item_number":"EX-99.1","item_title":"veraxabiotech_ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces the establishment of in vitro proof-of-concept data for VERAXA's novel BiTAC-ADC technology platform and the company's intention to launch partnering discussions at BIO International Convention 2026. The disclosure is primarily operational and strategic in nature—it describes a technology validation milestone and business development activity (partnering discussions) rather than a financial event, executive change, M\u0026A transaction, or other specifically enumerated event type. The data validation and partnering initiative represent material operational progress for an emerging biotech company, affecting investor assessment of the company's pipeline and commercial prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-08fd3440","taxonomy_version":"v1.2","classified_at":"2026-06-21T19:02:52.583393+00:00","company_name":"Veraxa Biotech Holding AG","ticker":null,"filing_date":"2026-06-18"}]}